Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -
Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram
Important Resources for the MS community are found on the left side of this blog.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, October 13, 2012
Friday, October 12, 2012
By John Gever, Senior Editor, MedPage Today
Thursday, October 11, 2012
Read and contact Outlook Life directly, if you need further information
WebMD Health News
Then please return here to leave comments
Wednesday, October 10, 2012
AMPYRA® Two-Year Safety Data Presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- Among the 62,400 patients who were prescribed AMPYRA during the first two years following
FDAapproval, 160 seizures were reported, or approximately 4.6 per 1000 patient-years of use. This rate is comparable to the rate of seizure seen in the overall MS population. Length of treatment prior to a seizure ranged from first dose to two years, with 20% of the seizures occurring within a week of starting treatment. Because of their disease, people with MS are at a higher risk of seizure than people who do not have MS.
- The most frequently reported AEs from
March 2010through March 2012were dizziness, insomnia, balance disorder, headache, nausea, urinary tract infection, back pain, and asthenia. These are similar to the AEs most frequently reported during AMPYRA clinical trials.
Tuesday, October 9, 2012
Monday, October 8, 2012
Acorda sinks after insurance provider questions MS drug
Theflyonthewall.com via Yahoo! Finance Mon, 08 Oct 2012 08:41 AM PDT
Acorda Therapeutics (ACOR) is retreating after Group Health, which provides health insurance to over 600,000 people in the Northwest, questioned the necessity of the company's multiple sclerosis treatment, ...
THIS IS B.S. everybody and we need to Voice our concerns.
IF the FDA approved the medications, then they must have found worth in the drug(s)
Click here to read the blog posting about Aetna and Then, Call Aetna to voice your resentment to their decision. The phone numbers are found at that posting.